IP Library Granted Patent US 11,713,475
Granted Patent B2
US 11,713,475 · App. 17/273,447 · Granted Aug 1, 2023

Fermentative production of oligosaccharides by total fermentation utilizing a mixed feedstock

Inventors: Stefan Jennewein (Bad Honnef, DE); Dirk Wartenberg (Gau-Algesheim, DE); Katja Parschat (Bonn, DE)
Assignee: Chr. Hansen HMO GmbH
C12P19/12C12N1/20C12N9/1051C12N9/1205C12N9/16C12N9/90C12P19/04C12P19/18C12N2500/34C12Y204/01038C12Y207/01004C12Y207/01011C12Y207/01056C12Y207/07009C12Y301/03011C12Y501/03002C12Y504/02002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,713,475
App. No.
17/273,447
Granted
Aug 1, 2023
Kind
B2
Abstract

Disclosed are genetically engineered microbial cells for the production of oligosaccharides comprising a galactose-β1,4-glucose moiety at their reducing end, wherein said microbial cells are able to produce said oligosaccharides in the absence of exogenously added lactose, and a method of producing said oligosaccharides using said microbial cells.

Claims (28)

1. A method for production of lactose or an oligosaccharide of interest which comprises a galactose-β1,4-glucose moiety at its reducing end, the method comprising:

a) providing a genetically engineered microbial cell, wherein said microbial cell comprises:

at least one glucose transporter for translocating glucose from the culture medium into the microbial cell's cytoplasm;

an UDP-galactose biosynthesis pathway;

at least one β-1,4-galactosyltransferase being able to galactosylate free glucose to intracellularly produce lactose; and

one or more of:

i) a fructose transporter, fructokinase-6 activity, and 6-phosphofructokinase-1 activity; and

ii) a fructose specific phosphotransferase system and 1-phosphofructokinase;

b) cultivating the microbial cell in a culture medium and under conditions that are permissive for production of said lactose or oligosaccharide of interest, wherein the culture medium comprises a mixture of glucose and fructose as main carbon source; and

c) recovering the lactose or oligosaccharide of interest from the culture medium and/or the microbial cell.

2. The method according to claim 1 , wherein the oligosaccharide of interest is a human milk oligosaccharide selected from 2′-fucosyllactose, 3-fucosyllactose, 2′,3-difucosyllactose, 3′-sialyllactose, 6′-sialyllactose, 3-fucosyl-3′-sialyllactose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-difucosylhexose I, lacto-N-difucosylhexaose II, lacto-N-sialylpentaose LSTa, LSTb, LSTc.

3. The method according to claim 1 , wherein the microbial cell is cultivated without exogenous supply of lactose.

4. The method of claim 1 , wherein the mixture of glucose and fructose is obtained by hydrolyzation of sucrose.

5. The method of claim 1 , wherein the at least one glucose transporter is selected from glucose facilitated diffusion proteins and glucose translocating permeases.

6. The method of claim 1 , wherein said microbial cell expresses or overexpresses at least one gene encoding the glucose transporter.

7. The method of claim 6 , wherein the microbial cell expresses or overexpresses at least one gene selected from glf, galP and functional variants thereof.

8. The method of claim 1 , wherein said microbial cell possesses a phosphoglucomutase, a UTP-glucose-1-phosphate-uridyltransferase, and a UDP-glucose 4-epimerase.

9. The method of claim 1 , wherein the β-1,4-galactosyltransferase is encoded by a gene selected from Neisseria meningitidis lgtB, Aggregatibacter aphrophilus lex-1, Pasteurella multocida galTpm1141 and functional variants thereof.

10. The method of claim 1 , wherein said microbial cell possesses at least one additional glycosyltransferase.

11. The method of claim 10 , wherein the at least one additional glycosyltransferase is selected from fucosyltransferases, sialyltransferases, glucosaminyltransferases and galactosyltransferases.

12. The method of claim 11 , wherein the additional glycosyltransferase is a fucosyltransferase, and wherein said microbial cell possesses a mannose-6-phosphate isomerase, a phosphomannomutase, a mannose-1-phosphate-guanylyltransferase, a GDP-mannose-4,6-dehydratase, a GDP-L-fucose synthase.

13. The method of claim 1 , wherein the microbial cell comprises a glucose-translocating phosphotransferase system.

14. The method of claim 1 , wherein the microbial cell comprises a fructose-1,6-bisphosphatase.

15. The method of claim 1 , wherein said microbial cell comprises a deletion or functional inactivation of a glucose-6-phosphate isomerase.

16. The method of claim 1 , wherein said microbial cell comprises an exporter protein or a permease exporting the oligosaccharide of interest from the cell.

17. The method of claim 16 , wherein said microbial cell comprises a sugar efflux transporter.

18. The method of claim 1 , wherein said microbial cell is a bacterial cell selected from bacteria of the genera Escherichia, Lactobacillus, Corynebacterium, Bacillus, Streptococcus, Enterococcus, Lactococcus and Clostidium.

19. The method of claim 18 , wherein the microbial cell is a bacterial cell selected from bacterial species of Escherichia coli, Corynebacterium glutamicum, Clotridium cellulolyticum, Clostridium ljungdahlii, Clostridium autoethanogenum, Clostridium acetobutylicum, Bacillus subtilis, Bacillus megaterium, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus helveticus, Lactobacillus delbrueckii , and Lactococcus lactis.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: CHR. HANSEN HMO GMBH
To: CHR. HANSEN A/S
Reel/Frame 070396/0299 →
CHANGE OF NAME Recorded Apr 6, 2022
From: JENNEWEIN BIOTECHNOLOGIE GMBH
To: CHR. HANSEN HMO GMBH
Reel/Frame 059617/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2021
From: JENNEWEIN, STEFAN; WARTENBERG, DIRK; PARSCHAT, KATJA
To: JENNEWEIN BIOTECHNOLOGIE GMBH
Reel/Frame 056492/0245 →
Priority Claims (1)
EP 18192898 · Sep 6, 2018 · regional
Continuity (1)
Related Publication 20210317493A1 · Oct 14, 2021